Glycylpressin (Terlipressin)

Glycylpressin is employed in clinical practice for several serious conditions related to portal hypertension and circulatory failure.

• Treatment of hepatorenal syndrome to improve renal perfusion.
• Control of acute variceal bleeding caused by portal hypertension.
• Adjunct therapy for severe hypotension in septic shock (off‑label use).
• Management of refractory ascites associated with advanced liver disease.
• Supportive care in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures.

Side effects of Glycylpressin vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common

• Headache
• Nausea or vomiting
• Abdominal discomfort
• Transient hypertension
• Flushing or warmth at the infusion site
• Diarrhea

Serious

• Myocardial ischemia or infarction
• Severe hypertension leading to cerebrovascular events
• Peripheral or mesenteric ischemia
• Cardiac arrhythmias
• Acute renal failure
• Pulmonary edema

Before initiating Glycylpressin therapy, clinicians should consider several safety factors.

• Assess cardiovascular status; avoid use in patients with uncontrolled coronary artery disease.
• Monitor blood pressure closely; adjust infusion if severe hypertension develops.
• Use cautiously in patients with existing renal impairment or acute kidney injury.
• Pregnancy category is not established; avoid use unless benefits outweigh potential risks.
• Evaluate for peripheral vascular disease, as vasoconstriction may exacerbate ischemia.
• Ensure proper intravenous access to reduce local tissue injury.

Glycylpressin may interact with other medications, requiring dose adjustments or monitoring.

Avoid

• Concurrent use of other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) due to additive hypertension risk.
• Drugs that increase risk of ischemic events, such as ergot alkaloids.

Use with caution

• Diuretics, which may amplify changes in blood volume and pressure.
• ACE inhibitors or ARBs, which can affect renal perfusion.
• Beta‑blockers, as they may mask tachycardia.
• Anticoagulants, because altered hemodynamics could affect bleeding risk.